These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38886779)

  • 1. Nintedanib combined with immunosuppressive agents improves forced vital capacity in connective tissue disease-associated PF-ILD: a single-center study.
    Ushio Y; Wakiya R; Kameda T; Nakashima S; Shimada H; Miyagi T; Sugihara K; Mino R; Mizusaki M; Chujo K; Kagawa R; Yamaguchi H; Kadowaki N; Dobashi H
    BMC Rheumatol; 2024 Jun; 8(1):27. PubMed ID: 38886779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical value of KL-6 for predicting the occurrence and severity of connective tissue disease-associated interstitial lung disease is not affected by CTD type or treatment.
    Xing H; Liang H
    PeerJ; 2024; 12():e17792. PubMed ID: 39131623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of serum Krebs von den lungen-6 as a diagnostic marker in connective tissue disease associated with interstitial lung disease.
    Ma H; Lu J; Song Y; Wang H; Yin S
    BMC Pulm Med; 2020 Jan; 20(1):6. PubMed ID: 31915006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline.
    Nagy A; Nagy T; Kolonics-Farkas AM; Eszes N; Vincze K; Barczi E; Tarnoki AD; Tarnoki DL; Nagy G; Kiss E; Maurovich-Horvat P; Bohacs A; Müller V
    Front Pharmacol; 2021; 12():778649. PubMed ID: 35002713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience.
    Boutel M; Boutou A; Pitsiou G; Garyfallos A; Dimitroulas T
    Diagnostics (Basel); 2023 Mar; 13(7):. PubMed ID: 37046439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease.
    Lee JS; Lee EY; Ha YJ; Kang EH; Lee YJ; Song YW
    Arthritis Res Ther; 2019 Feb; 21(1):58. PubMed ID: 30764869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.
    Maher TM; Tudor VA; Saunders P; Gibbons MA; Fletcher SV; Denton CP; Hoyles RK; Parfrey H; Renzoni EA; Kokosi M; Wells AU; Ashby D; Szigeti M; Molyneaux PL;
    Lancet Respir Med; 2023 Jan; 11(1):45-54. PubMed ID: 36375479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of antifibrotic agents in the treatment of CTD-ILD and RA-ILD: A systematic review and meta-analysis.
    Yang M; Wu Y; Liu X; Zhao C; Li T; Li T; Zhang X; Jiang H; Mao B; Liu W
    Respir Med; 2023 Sep; 216():107329. PubMed ID: 37315742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung function trajectory in progressive fibrosing interstitial lung disease.
    Oldham JM; Lee CT; Wu Z; Bowman WS; Pugashetti JV; Dao N; Tonkin J; Seede H; Echt G; Adegunsoye A; Chua F; Maher TM; Garcia CK; Strek ME; Newton CA; Molyneaux PL
    Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34737223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias.
    Yıldırım F; Türk M; Bitik B; Erbaş G; Köktürk N; Haznedaroğlu Ş; Türktaş H
    Kaohsiung J Med Sci; 2019 Jun; 35(6):365-372. PubMed ID: 30913371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab for connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.
    Wang Y; Li L
    Int J Rheum Dis; 2023 Feb; 26(2):225-235. PubMed ID: 36378118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Efficacy and Safety of Pirfenidone Combined With Immunosuppressant Therapy in Connective Tissue Disease-Associated Interstitial Lung Disease: A 24-Week Prospective Controlled Cohort Study.
    Wang J; Wang X; Qi X; Sun Z; Zhang T; Cui Y; Shu Q
    Front Med (Lausanne); 2022; 9():871861. PubMed ID: 35646960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing prognostic factors correlating with response to nintedanib for connective tissue disease-associated interstitial lung disease: A real-world single-center study.
    Kokubu H; Takeuchi S; Tozawa T; Hisada S; Yamada Y; Itoh Y; Kodera M
    Int J Rheum Dis; 2023 Apr; 26(4):682-688. PubMed ID: 36808836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The diagnostic value of serum KL-6 in connective tissue disease associated interstitial lung disease].
    Wu X; Wu LJ; Luo CN; Shi YM; Zou JM; Meng XY
    Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3172-3175. PubMed ID: 31694110
    [No Abstract]   [Full Text] [Related]  

  • 16. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process.
    Roofeh D; Barratt SL; Wells AU; Kawano-Dourado L; Tashkin D; Strand V; Seibold J; Proudman S; Brown KK; Dellaripa PF; Doyle T; Leonard T; Matteson EL; Oddis CV; Solomon JJ; Sparks JA; Vassallo R; Maxwell L; Beaton D; Christensen R; Townsend W; Khanna D
    Semin Arthritis Rheum; 2021 Dec; 51(6):1331-1341. PubMed ID: 34493396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of rheumatoid factor and anti-citrullinated peptides in fibrotic interstitial lung disease.
    Zheng B; Donohoe K; Hambly N; Johannson KA; Assayag D; Fisher JH; Manganas H; Marcoux V; Khalil N; Kolb M; Ryerson CJ;
    Respirology; 2022 Oct; 27(10):854-862. PubMed ID: 35652240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in connective tissue disease-associated interstitial lung disease.
    Duarte AC; Cordeiro A; Fernandes BM; Bernardes M; Martins P; Cordeiro I; Santiago T; Seixas MI; Ribeiro AR; Santos MJ
    Clin Rheumatol; 2019 Jul; 38(7):2001-2009. PubMed ID: 31016581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.